Abstract
BackgroundTreatment with immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) can yield remarkable anti-tumor responses in lung cancer patients, however, not all patients respond to ICIs. Biomarkers currently used in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have